AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2475 companies scored · 2026-10-14 run in progress: 4479 of ~5379 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-14 run
Companies scored 2475 IC ≥ 0 · market cap ≥ $100M
Median forecast +0.26% Alpha · 90D
Long–short spread +4.14% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 90D
Rating changes ▲ 109 ▼ 24 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

286 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
151 DNAGinkgo Bioworks Holdings, Inc. Life Sciences 0.23 $792M Unlock rating and forecasts
152 CRVSCorvus Pharmaceuticals, Inc. Life Sciences 0.33 $792M Unlock rating and forecasts
153 ARDXARDELYX, INC. Life Sciences 0.28 $777M Unlock rating and forecasts
154 GERNGERON CORP Life Sciences 0.39 $771M Unlock rating and forecasts
155 GYREGYRE THERAPEUTICS, INC. Life Sciences 0.01 $748M Unlock rating and forecasts
156 ANNXAnnexon, Inc. Life Sciences 0.41 $726M Unlock rating and forecasts
157 SANASana Biotechnology, Inc. Life Sciences 0.30 $721M Neutral +0.54% -0.02% ·
158 LXRXLEXICON PHARMACEUTICALS, INC. Life Sciences 0.16 $716M Unlock rating and forecasts
159 CADLCandel Therapeutics, Inc. Life Sciences 0.04 $709M Unlock rating and forecasts
160 COLLCOLLEGIUM PHARMACEUTICAL, INC Life Sciences 0.52 $701M Neutral +0.18% -0.27% ·
161 FDMT4D Molecular Therapeutics, Inc. Life Sciences 0.04 $682M Unlock rating and forecasts
162 VSTMVerastem, Inc. Life Sciences 0.51 $675M Unlock rating and forecasts
163 AURAAura Biosciences, Inc. Life Sciences 0.45 $650M Unlock rating and forecasts
164 SLDBSolid Biosciences Inc. Life Sciences 0.41 $624M Unlock rating and forecasts
165 IMMXImmix Biopharma, Inc. Life Sciences 0.22 $622M Unlock rating and forecasts
166 WVEWave Life Sciences, Inc. Life Sciences 0.49 $619M Neutral +0.19% -0.48% ·
167 ZVRAZEVRA THERAPEUTICS, INC. Life Sciences 0.28 $617M Unlock rating and forecasts
168 OLMAOlema Pharmaceuticals, Inc. Life Sciences 0.53 $614M Unlock rating and forecasts
169 DSGNDesign Therapeutics, Inc. Life Sciences 0.43 $612M Unlock rating and forecasts
170 PRMEPrime Medicine, Inc. Life Sciences 0.24 $602M Unlock rating and forecasts
171 IRWDIRONWOOD PHARMACEUTICALS INC Life Sciences 0.42 $593M Unlock rating and forecasts
172 CLYMClimb Bio, Inc. Life Sciences 0.27 $592M Unlock rating and forecasts
173 AQSTAquestive Therapeutics, Inc. Life Sciences 0.14 $586M Unlock rating and forecasts
174 CRMDCorMedix Inc. Life Sciences 0.43 $576M Unlock rating and forecasts
175 PHATPhathom Pharmaceuticals, Inc. Life Sciences 0.24 $566M Unlock rating and forecasts
176 IVAInventiva S.A. Life Sciences 0.24 $555M Unlock rating and forecasts
177 STTKShattuck Labs, Inc. Life Sciences 0.35 $551M Unlock rating and forecasts
178 EOLSEvolus, Inc. Life Sciences 0.57 $512M Unlock rating and forecasts
179 ACRSAclaris Therapeutics, Inc. Life Sciences 0.34 $511M Unlock rating and forecasts
180 CTMXCytomX Therapeutics, Inc. Life Sciences 0.02 $507M Unlock rating and forecasts
181 SGMTSagimet Biosciences Inc. Life Sciences 0.37 $496M Neutral +0.32% +0.35% ·
182 MNPRMonopar Therapeutics Life Sciences 0.07 $484M Unlock rating and forecasts
183 RGNXREGENXBIO Inc. Life Sciences 0.04 $479M Unlock rating and forecasts
184 ARVNARVINAS, INC. Life Sciences 0.28 $447M Neutral +0.37% -0.02% new
185 ALLOAllogene Therapeutics, Inc. Life Sciences 0.34 $446M Unlock rating and forecasts
186 TLRYTilray Brands, Inc. Life Sciences 0.01 $445M Unlock rating and forecasts
187 ADXNAddex Therapeutics Ltd. Life Sciences 0.01 $445M Neutral +0.23% +0.19% ·
188 TKNOAlpha Teknova, Inc. Life Sciences 0.46 $441M Unlock rating and forecasts
189 NGNENeurogene Inc. Life Sciences 0.13 $431M Unlock rating and forecasts
190 NIKANIKA PHARMACEUTICALS, INC Life Sciences 0.19 $431M Unlock rating and forecasts
191 AUTLAutolus Therapeutics plc Life Sciences 0.40 $431M Unlock rating and forecasts
192 ENTXEntera Bio Ltd. Life Sciences 0.26 $431M Unlock rating and forecasts
193 PRTAPROTHENA CORP PUBLIC LTD CO Life Sciences 0.31 $429M Neutral +0.27% -0.11% ·
194 OVIDOvid Therapeutics Inc. Life Sciences 0.01 $428M Unlock rating and forecasts
195 TECXTectonic Therapeutic, Inc. Life Sciences 0.02 $417M Unlock rating and forecasts
196 ASMBASSEMBLY BIOSCIENCES, INC. Life Sciences 0.14 $414M Neutral +0.55% +0.19% ·
197 ZURAZura Bio Ltd Life Sciences 0.25 $405M Unlock rating and forecasts
198 SPRYARS Pharmaceuticals, Inc. Life Sciences 0.27 $403M Neutral +0.94% +0.05% ·
199 CAPRCAPRICOR THERAPEUTICS, INC. Life Sciences 0.49 $400M Unlock rating and forecasts
200 MYGNMYRIAD GENETICS INC Life Sciences 0.50 $390M Unlock rating and forecasts
151–200 of 286 Previous Next
Since the previous run

Rating changes

▲ 109▼ 24
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-14) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.